How patients use CINQAIR® (reslizumab) Injection Cost Support Program Card
Reslizumab: First Global Approval | Drugs
Reslizumab
Teva's Asthma Therapy Reslizumab Fails in Late-Stage Studies
Teva anuncia la aprobación y lanzamiento de Cinqaero en España
Teva-Handok wins approval for anti-asthma injection < Pharma < Article - KBR
CINQAIR® (reslizumab) Injection – About Asthma Control
Reslizumab - Medication Detail | Asthma Initiative of Michigan (AIM)
Real-World Effectiveness of Reslizumab in Patients With Severe Eosinophilic Asthma – First Initiators and Switchers - ScienceDirect
Teva files MAA for asthma treatment reslizumab
Israeli Pharma gets FDA Approval for Asthma Antibody
CINQAIR- reslizumab injection, solution, concentrate
Teva's Asthma Segment: What Could Boost Its Revenues in 2016?
Cinqair: Package Insert - Drugs.com
Teva's Severe Asthma Therapy Reslizumab Now Approved in Europe | RT
New Drug Product: Cinqair - MPR
Reslizumab Overview - Creative Biolabs
CINQAERO - Tevacare
Reslizumab in the treatment of inadequately controlled asthma in adults and adolescents with elevated blood eosinophils: clinical trial evidence and future prospects - Jorge Máspero, 2017
CINQAIR® (reslizumab) Injection – About Asthma Control
Effect of fixed-dose subcutaneous reslizumab on asthma exacerbations in patients with severe uncontrolled asthma and corticosteroid sparing in patients with oral corticosteroid-dependent asthma: results from two phase 3, randomised, double-blind ...
Teva's Cinqaero for Severe Asthma Treatment Gets EC Marketing OK
Teva's severe eosinophilic asthma drug Cinqaero wins EU approval
